Posts by: Steve Bryson PhD

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to sotatercept for the treatment of pulmonary arterial hypertension (PAH), according to Acceleron Pharma, the therapy’s manufacturer. ... Read more

September 9, 2019September 11, 2019

Two Non-Invasive Tests Predict PAH Prognosis in Patients with Congenital Heart Disease, Study Reveals

News, PAH News

Only two non-invasive diagnostic tests are required to best predict the risk of adverse events in people with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH), a new study ... Read more

August 23, 2019August 28, 2019

Targeting Feedback Signaling Mechanism Involved in Vascular Remodeling May Prevent PH, Study Finds

News

Disrupting the vascular remodeling feedback signaling loop mediated by CD146-HIF-1α can effectively prevent the development of pulmonary hypertension (PH) in mice, a study found. This suggests that medicines that could ... Read more

August 8, 2019August 9, 2019

Interleukin-1 Receptor Antagonist Reduces PH in Newborn Mice, Study Finds

News, PH News

Blocking the protein interleukin-1 (IL-1) protects against pulmonary hypertension (PH) induced by complications from bronchopulmonary dysplasia (BPD) caused by high levels of oxygen, a new study in newborn mice ... Read more

Posts by: Steve Bryson PhD

Steve Bryson PhD

Acceleron’s Sotatercept Receives FDA’s Orphan Drug Status for PAH

Two Non-Invasive Tests Predict PAH Prognosis in Patients with Congenital Heart Disease, Study Reveals

Targeting Feedback Signaling Mechanism Involved in Vascular Remodeling May Prevent PH, Study Finds

Interleukin-1 Receptor Antagonist Reduces PH in Newborn Mice, Study Finds

Pin It on Pinterest